Short-term effect of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion

Retina

Volumn 36, Issue 9, 2016, Pages 1726-1732

  Minami, Yoshiro ^a   Nagaoka, Taiji ^b   Ishibazawa, Akihiro ^a,b   Yoshida, Akitoshi ^b  

^a Nayoro City General Hospital   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MACULAR EDEMA; MALE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PROSPECTIVE STUDY; RETINA FOVEA; RETINA VEIN OCCLUSION; SLIT LAMP; ANTAGONISTS AND INHIBITORS; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; RETINAL VEIN OCCLUSION; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; PROSPECTIVE STUDIES; RANIBIZUMAB; RECURRENCE; RETINAL VEIN OCCLUSION; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84957831404     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000991     Document Type: Article

References (26)

1. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-141; discussion 141-133.
2. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-319.e311.
3. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: An evidence-based systematic review. Ophthalmology 2010;117:1094-1101.e1095.
4. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984;98:271-282.
5. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112.e1101.
6. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-1602.
7. Sophie R, Hafiz G, Scott AW, et al. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol 2013;156:693-705.
8. Brynskov T, Kemp H, Sorensen TL. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice. Retina 2014;34:1637-1643.
9. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:807-822.
10. Welch DE, Elmariah H, Peden MC, et al. Short-term response of macular oedema to intravitreal bevacizumab. Br J Ophthalmol 2009;93:1033-1036.
11. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
12. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-544.
13. Ahn SJ, Ahn J, Park S, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2014;55:567-573.
14. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: Efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008;49:4523-4527.
15. Ach T, Hoeh AE, Schaal KB, et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:155-159.
16. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
17. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140:256-261.
18. Noma H, Mimura T, Yasuda K, et al. Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci 2014;55:3878-3885.
19. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
20. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 2008;22:42-48.
21. Thach AB, Yau L, Hoang C, et al. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 2014; 121:1059-1066.
22. Jaissle GB, Szurman P, Feltgen N, et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2011;249:183-192.
23. Chung EJ, Hong YT, Lee SC, et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1241-1247.
24. Kang HM, Chung EJ, Kim YM, et al. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2013;251:501-508.
25. Gallego-Pinazo R, Dolz-Marco R, Pardo-Lopez D, et al. Ranibizumab for serous macular detachment in branch retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol 2013;251:9-14.
26. Yuka I, Yoshitsugu S, Osamu S, et al. Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion. Clin Ophthalmol 2015;9:175-180.